Clinical TrialJun 1, 2026, 10:03 AM
Valneva's Lyme Disease Vaccine Partner Pfizer Reports Positive Phase 3 Results
AI Summary
Valneva announced that its partner Pfizer reported positive topline Phase 3 results for their Lyme disease vaccine candidate, demonstrating strong efficacy with no safety concerns. Pfizer is now planning submissions to regulatory authorities. Additionally, Valneva will engage with institutional investors at three conferences in June: Jefferies Global Healthcare Conference, Oddo BHF Nextcap Forum, and BNP Paribas SMID Cap Conference. The Company will also be a Gold Sponsor and Exhibitor at the 10th Northern European Conference on Travel Medicine.
Key Highlights
- Pfizer reported positive topline Phase 3 results for Valneva's Lyme disease vaccine candidate.
- The vaccine demonstrated strong efficacy with no safety concerns in Phase 3 trials.
- Pfizer is preparing to submit the vaccine for regulatory approvals.
- Valneva to participate in Jefferies Global Healthcare Conference on June 3.
- Valneva to attend Oddo BHF Nextcap Forum on June 12.
- Valneva to attend BNP Paribas SMID Cap Conference on June 24.
- Valneva is a Gold Sponsor and Exhibitor at NECTM10 from June 3-5.
Price Impact
More from VALN